CA Patent

CA2726244A1 — Dpp-iv inhibitors for use in the treatment of nafld

Assigned to Boehringer Ingelheim International GmbH · Expires 2009-12-10 · 16y expired

What this patent protects

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).

USPTO Abstract

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).

Drugs covered by this patent

Patent Metadata

Patent number
CA2726244A1
Jurisdiction
CA
Classification
—
Expires
2009-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.